Kyu-pyo E. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 194 publications

Molecular profiling of pancreatic acinar cell carcinoma and amphicrine-like carcinoma: high frequency of homologous recombination deficiency and molecular heterogeneity.

Molecular profiling of pancreatic acinar cell carcinoma and amphicrine-like carcinoma: high frequency of homologous recombination deficiency and molecular heterogeneity.

Journal: Histopathology

Published: August 06, 2026

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Journal: Journal of hepatology

Published: April 09, 2026

Updates on Imaging Assessment of Pancreatic Cancer for Determining Anatomic and Biologic Resectability.

Updates on Imaging Assessment of Pancreatic Cancer for Determining Anatomic and Biologic Resectability.

Journal: Korean journal of radiology

Published: March 07, 2026

Erlotinib Induces Cell Death by Blocking NIX-mediated Mitophagy Through Lysosomal Swelling in IDH1-mutant Cholangiocarcinoma.

Erlotinib Induces Cell Death by Blocking NIX-mediated Mitophagy Through Lysosomal Swelling in IDH1-mutant Cholangiocarcinoma.

Journal: Anticancer research

Published: December 18, 2025

Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOX.

Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOX.

Journal: Frontiers in oncology

Published: December 07, 2025

Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers.

Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers.

Journal: International journal of clinical oncology

Published: December 04, 2025

Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine Learning.

Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine Learning.

Journal: JCO clinical cancer informatics

Published: December 02, 2025

Molecular epidemiology and outcomes of EGFR exon 20 insertion in Korean patients with non-small cell lung cancer.

Molecular epidemiology and outcomes of EGFR exon 20 insertion in Korean patients with non-small cell lung cancer.

Journal: Translational lung cancer research

Published: November 30, 2025

Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic Potential.

Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic Potential.

Journal: Targeted oncology

Published: October 01, 2025

Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial.

Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial.

Journal: JAMA network open

Published: October 01, 2025

Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial.

Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial.

Journal: Annals of surgical oncology

Published: September 16, 2025

Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.

Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.

Journal: The oncologist

Published: September 05, 2025

Showing 1-12 of 194

Last Updated: 09/26/2026